BR[AI]N
Prediction of conversion to Alzheimer's Disease
Breakthrough DeviceActive
Key Facts
Indication
Prediction of conversion to Alzheimer's Disease
Phase
Breakthrough Device
Status
Active
Company
About Ainostics
Ainostics is a private, clinical-stage AI diagnostics company leveraging advanced machine learning and medical imaging to transform the detection and prognosis of neurological diseases like Alzheimer's, Multiple Sclerosis, and brain tumors. The company has achieved significant milestones, including FDA Breakthrough Device designation for its BR[AI]N product and securing approximately $6 million in funding to date. With a strong academic and clinical collaboration network, Ainostics aims to integrate its solutions into routine clinical practice and global pharmaceutical trials to enable earlier, more personalized interventions.
View full company profile